{"entity":{"id":"nct06797999","kind":"trial","name":"First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma","aka":["ADCElerate1"],"tldr":"A phase 1/2 trial of Antibody-drug conjugate (ADC) in sarcomas, run by Adcendo ApS, now recruiting.","summary":"First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma is a phase 1/2 interventional study registered as NCT06797999 by Adcendo ApS, with 270 participants planned, started 2025-06-05 and due to reach its primary completion in 2029-02-27. Interventions recorded: Antibody-drug conjugate (ADC).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06797999","url":"https://clinicaltrials.gov/study/NCT06797999"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":["adc"],"targets":["top1"],"drugs":[],"companies":["adcendo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06797999","phase":"1/2","setting":"A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma","sponsor":"Adcendo ApS","started":"2025-06-05","startedType":"actual","enrolled":270,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06797999/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"top1","kind":"target","name":"Topoisomerase I (TOP1)","route":"/targets/top1/"}],"company":[{"id":"adcendo","kind":"company","name":"Adcendo","route":"/companies/adcendo/"}]}}